Why the study?
The Supraflex Cruz SES provides enhanced flexibility and pushability and may compete with current best-in-class stents in complex lesions, but noninferiority versus SYNERGY EES in 3VD undergoing state-of-the-art PCI had not been demonstrated.
Does the Supraflex Cruz SES reduce the 1-year patient-oriented composite endpoint compared to the SYNERGY EES in patients with de novo 3-vessel disease undergoing state-of-the-art PCI?
Does the Supraflex Cruz SES reduce the 1-year patient-oriented composite endpoint compared to the SYNERGY EES in patients with de novo 3-vessel disease undergoing state-of-the-art PCI?
In patients with 3-vessel disease treated with state-of-the-art PCI, the Supraflex Cruz stent is non-inferior to the SYNERGY stent for the 1-year patient-oriented composite endpoint.
Answers are grounded in this paper and cite their sources.
Broadens DES options for state-of-the-art 3VD PCI; extends evidence for ultra-thin strut biodegradable-polymer SES in complex CAD.[[1]](https://eurointervention.pcronline.com/article/a-randomized-controlled-trial-to-compare-the-safety-and-efficacy-of-sirolimus-eluting-biodegradable-polymer-ultra-thin-stent-supraflex-cruz-and-everolimus-eluting-biodegradable-polymer-stent-synergy-in-treatment-for
Background Clinical outcomes after PCI for three-vessel disease (3VD) have improved with best-practice strategies exemplified by the SYNTAX II trial. The Supraflex Cruz SES, featuring a long valley-to-valley Z-connector, provides enhanced flexibility and pushability and may compete with the current best-in-class stents in complex lesions. Purpose We aimed to demonstrate the noninferiority of the Supraflex Cruz SES versus SYNERGY EES with patient oriented composite endpoint (POCE) with 3VD undergoing State-of-the-art PCI. Methods The Multivessel TALENT trial is a prospective, multicentre (54 centres across Europe), open-label, randomized controlled study comparing the clinical outcomes of PCI with Supraflex Cruz stents versus SYNERGY stents in patients with de novo 3VD without left main involvement. State-of-the-art PCI was applied to all patients, encompassing Heart Team decision-making guided by the SYNTAX Score II, functional assessment using quantitative flow ratio (QFR) by an independent corelab, stent optimization with IVUS/OCT, and prasugrel monotherapy following one month of dual antiplatelet therapy (DAPT). The primary endpoint was the one-year POCE, defined as all-cause death, any stroke, any myocardial infarction, or any revascularisation assessed in a non-inferiority statistical scheme. Results Between September 22, 2020, and September 26, 2024, a total of 1,548 patients were randomly assigned to treatment (774 in each group). At 12 months, the primary endpoint occurred in 117 patients (15.3%) in the Supraflex Cruz group and in 111 patients (14.6%) in the SYNERGY group (absolute difference −0.73% [one-sided 95% upper confidence bound 3.73%]; p for non-inferiority <0.026)(Figure 1A and B). The assumed event rate was 10.7% in each group; however, the observed rate was higher than expected, primarily driven by a greater number of periprocedural myocardial infarctions adjudicated according to the SCAI criteria. Based on the observed event rate of 14.6%, the corresponding non-inferiority margin was 5.83%, yielding a p-value for non-inferiority of <0.001. In a sensitivity analysis excluding periprocedural myocardial infarction (POCE without PPMI), as used in the NOBLE trial, the POCE event rate was 9.7% in the SYNERGY group and 9.2% in the Supraflex Cruz group; the risk difference was not statistically significant. (Figure C) In a predefined subgroup analysis assessing POCE in the three strata of the anatomical (SYNTAX Score (SS≤22, 23-32, ≥33), the event rate in the highest strata of the Supraflex Cruz was numerically lower than in the SYNERGY arm. (14.6% in Supraflex Cruz and 22.8% in SYNERGY arm, p = 0.167)(Figure D) Conclusions In 3VD patients treated with the best PCI practice, the Supraflex Cruz stent is non-inferior to the SYNERGY stent in terms of POCE at one year. The potential superiority of the Supraflex Cruz in the most complex patients (SS ≥33) must be further investigated.
No takes yet. Share an insight, caveat, or question.
Serruys et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: